PROC 001
Alternative Names: PROC-001; Stem cell therapeutics - Procella Therapeutics/SmartwiseLatest Information Update: 09 Aug 2023
At a glance
- Originator Procella Therapeutics; Smartwise
- Developer AstraZeneca
- Class Cardiovascular therapies; Heart failure therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Heart failure
Most Recent Events
- 28 Jul 2023 PROC 001 is still in early research for Heart failure in Sweden (Intracardiac, Injection)
- 28 Jun 2022 No recent reports of development identified for research development in Heart-failure in Sweden (Intracardiac, Injection)
- 19 Oct 2021 Procella Therapeutics plans a first-in-human clinical trial for Heart failure in an undisclosed location (Procella Therapeutics website, October 2021)